Bulletin of Experimental Biology and Medicine

, Volume 149, Issue 5, pp 587–590 | Cite as

Blood Levels of Inflammatory and Destructive Biomarkers in Coronary Atherosclerosis of Different Severity

  • Yu. I. Ragino
  • A. M. Chernjavski
  • Ya. V. Polonskaja
  • S. Yu. Tchimbal
  • D. A. Redjkin
  • E. V. Semaeva
  • E. V. Kashtanova
  • M. I Voevoda
Article

In male patients with coronary atherosclerosis without acute coronary syndrome, the levels of inflammatory-destructive biomarkers of atherosclerotic plaque instability depended on the severity and dissemination of coronary atherosclerosis. The highest levels of C-reactive protein and matrix metalloproteinase 3 were found in men with atherosclerotic involvement of all three main coronary arteries, primarily their middle and distal segments, and in men with predominance of low-grade stenoses (<50%) of coronary arteries in areas of atherosclerotic plaques.

Key Words

coronary atherosclerosis biomarkers of atherosclerotic plaque instability highly sensitive C-reactive protein metalloproteinases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yu. I. Ragino, A. M. Cherjyavski, Ya. V. Polonskaja, et al., Byull. Eksp. Biol. Med., 144, No. 11, 500–503 (2007).Google Scholar
  2. 2.
    Yu. I. Ragino, A. M. Chernjavski, Ya. V. Polonskaja, et al., Kardiologiya, No. 9, 62–67 (2007).Google Scholar
  3. 3.
    E. J. Armstrong, D. A. Morrow, and M. S. Sabatine, Circulation, 113, No. 6, e72–75 (2006).CrossRefPubMedGoogle Scholar
  4. 4.
    E. J. Armstrong, D. A. Morrow, and M. S. Sabatine, Ibid., 113, No. 7, e152–155 (2006).CrossRefPubMedGoogle Scholar
  5. 5.
    E. J. Armstrong, D. A. Morrow, and M. S. Sabatine, Ibid., 113, No. 9, e382–385 (2006).CrossRefPubMedGoogle Scholar
  6. 6.
    M. Asakura, Y. Ueda, O. Yamaguchi, et al., J. Am. Coll Cardiol., 37, No. 5, 1284–1288 (2001).CrossRefPubMedGoogle Scholar
  7. 7.
    J. C. Fruchart, Handbook of Dyslipidemia and Atherosclerosis. France, University of Lille (2003), Pt. 1. pp. 1–65.Google Scholar
  8. 8.
    J. A. Goldstein, D. Demetriou, C. L. Grines, et al., N. Engl. J. Med., 343, No. 13, 915–922 (2000).CrossRefPubMedGoogle Scholar
  9. 9.
    D. G. Katritsis, J. Pantos, and E. Efstathopoulos, Coron. Artery Dis., 18, No. 3, 229–237 (2007).CrossRefPubMedGoogle Scholar
  10. 10.
    M. Naghavi, E. Falk, H. S. Hecht, et al., Am. J. Cardiol., 98, No. 2A, 2H–15H (2006).CrossRefPubMedGoogle Scholar
  11. 11.
    M. Naghavi, P. Libby, E. Falk, et al., Circulation, 108, No. 14, 1664–1672 (2003).CrossRefPubMedGoogle Scholar
  12. 12.
    P. J. Scanlon, D. P. Faxon, A. M. Audet, et al., J. Am. Coll Cardiol., 33, No. 6, 1756–1824 (1999).CrossRefPubMedGoogle Scholar
  13. 13.
    P. K. Shah, High-Risk Atherosclerotic Plaques: Mechanisms, Imaging, Models, and Therapy. Ed. L. M. Khachigian, New York (2005), pp. 1–19.Google Scholar
  14. 14.
    P. K. Shah and B. Sharifi , Biochemistry of Atherosclerosis, Ed. S. K. Cheema, New York (2006), pp. 455–563.Google Scholar
  15. 15.
    R. Waksman and P. W. Seruys, Handbook of the Vulnerable Plaque. London (2004), pp. 1–48.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2010

Authors and Affiliations

  • Yu. I. Ragino
    • 1
  • A. M. Chernjavski
    • 2
  • Ya. V. Polonskaja
    • 1
  • S. Yu. Tchimbal
    • 2
  • D. A. Redjkin
    • 2
  • E. V. Semaeva
    • 2
  • E. V. Kashtanova
    • 1
  • M. I Voevoda
    • 1
  1. 1.Institute of TherapySiberian Division of Russian Academy of Medical SciencesNovosibirskRussia
  2. 2.E. N. Meshalkin Research Institute of Circulatory PathologyFederal Agency for High-Technological Medical CareNovosibirskRussia

Personalised recommendations